Loading...
By Kelly Young
Edited by David G. Fairchild, MD, MPH
The American Heart Association, the American College of Cardiology, and the Heart Rhythm Society have released guidelines on treating patients who have ventricular arrhythmias or otherwise are at risk for sudden cardiac death. This is an update from the groups' 2006 guidance.
Among the many recommendations:
For patients with NYHA class IV symptoms who aren't hospitalized and are candidates for a left ventricular assist device or cardiac transplantation, an implantable cardioverter defibrillator (ICD) is an acceptable option if the patient's expected meaningful survival is at least 1 year.
For patients with nonischemic cardiomyopathy, ICDs are recommended in patients who survive sudden cardiac arrest due to ventricular tachycardia (VT)/ventricular fibrillation or who experience hemodynamically unstable VT or stable VT unrelated to reversible causes.
A subcutaneous ICD is recommended for patients who have inadequate vascular access or are at high infection risk from an ICD, and for whom pacing (for bradycardia or VT termination or as part of cardiac resynchronization) is not required.
Comment
LINK(S):
JACC article (Free PDF)
Background: NEJM Journal Watch Cardiologycoverage of European guidelines on ventricular arrhythmia (Your NEJM Journal Watch registration required)